Datasets:

mathom

/

ct_dataset

like 0

<s>[INST] Provide title for trial id: NCT04550910 [/INST] RCT Comparing 2 Radiotherapy HypoFractionation Schedules In Breast Cancer Patients </s>

<s>[INST] Provide the recruitment status for trial id: NCT04550910 [/INST] Unknown status </s>

<s>[INST] Provide the medical condition for trial id: NCT04550910 [/INST] Radiotherapy Side Effect, Locoregional Recurrence </s>

<s>Trial Id: Persistent Organic Pollutants and Breast Cancers (POPCASE) Recruitment Status: Recruiting Trail description: Exposure to certain classes of chemical contaminants, including certain persistent organic pollutants (POPs) with a character of endocrine disruptors, could be one of the factors that lead to increase incidence of breast cancer in the Western world . However, the causal role of POPs in the onset of breast cancer remains nowadays unproven. Preliminary epidemiological studies on the impact of these environmental factors in breast cancer etiology have ignored the critical periods of exposure. Similarly, they have considered a limited number of pollutants (not including possible joint or synergistic effects between individual compounds) and did not distinguish the different breast cancer subtypes may have different etiologies or even of genetic susceptibility factors (POP polymorphism of detoxification enzymes). Thus, POPCASE study examines the association between the presence of breast cancer and the levels and exposure profiles to a group of POPs measured in adipose tissue (AT) and blood, in particular using spectrometric methods developed by the team LABERCA (Nantes, France). These internal levels of POPs (organochlorine pesticides, dioxins, PCBs, brominated flame retardants) will be measured both quantitatively (tissue concentrations) and qualitative (relative proportions of different pollutants sought). Inclusion Criteria: Women ≥ 18 and <75 years According to the arm: Arm A: histologically confirmed diagnosis of invasive breast cancer (only), unilateral or bilateral, outside off recurrence and relapse. Patients who have been supported for a contralateral breast cancer can be included if a period of at least 2-years between the last systemic treatment of inclusion in the study. Arm B: Any woman operated on for breast plastic surgery (breast lift and breast reduction cure only) Performance status (WHO) ≤ 1 5. Patient affiliated to a social security scheme, 6. Patient who signed and dated informed consent form 7. Arm A only: unifocal lesion 8. Arm A only: Clinical stage M0 Exclusion Criteria: Patient with uncontrolled infection Patient pregnant or lactating Patient with a viral infection (HIV, Hepatitis B, Hepatitis C) Patient cannot be regularly monitored for psychological reasons, social, family or geographical. Patient Private of liberty or under a guardianship authority / curatorship. Arm A only: Patient to benefit from neoadjuvant therapy for breast cancer Arm A only Patient with metastatic breast cancer Arm A only Patient diagnosed cancer in situ (intra ductal) Arm A only Patient with BRCA1 or BRCA2 known Arm B only: previous breast plastic surgery, regardless of the type of intervention </s>

<s>[INST] Provide inclusion criteria for trial id: NCT02890095 [/INST] Women ≥ 18 and <75 years According to the arm: Arm A: histologically confirmed diagnosis of invasive breast cancer (only), unilateral or bilateral, outside off recurrence and relapse. Patients who have been supported for a contralateral breast cancer can be included if a period of at least 2-years between the last systemic treatment of inclusion in the study. Arm B: Any woman operated on for breast plastic surgery (breast lift and breast reduction cure only) Performance status (WHO) ≤ 1 5. Patient affiliated to a social security scheme, 6. Patient who signed and dated informed consent form 7. Arm A only: unifocal lesion 8. Arm A only: Clinical stage M0 </s>

<s>[INST] Provide exclusion criteria for trial id: NCT02890095 [/INST] Patient with uncontrolled infection Patient pregnant or lactating Patient with a viral infection (HIV, Hepatitis B, Hepatitis C) Patient cannot be regularly monitored for psychological reasons, social, family or geographical. Patient Private of liberty or under a guardianship authority / curatorship. Arm A only: Patient to benefit from neoadjuvant therapy for breast cancer Arm A only Patient with metastatic breast cancer Arm A only Patient diagnosed cancer in situ (intra ductal) Arm A only Patient with BRCA1 or BRCA2 known Arm B only: previous breast plastic surgery, regardless of the type of intervention </s>

<s>[INST] Provide description for trial id: NCT02890095 [/INST] Exposure to certain classes of chemical contaminants, including certain persistent organic pollutants (POPs) with a character of endocrine disruptors, could be one of the factors that lead to increase incidence of breast cancer in the Western world . However, the causal role of POPs in the onset of breast cancer remains nowadays unproven. Preliminary epidemiological studies on the impact of these environmental factors in breast cancer etiology have ignored the critical periods of exposure. Similarly, they have considered a limited number of pollutants (not including possible joint or synergistic effects between individual compounds) and did not distinguish the different breast cancer subtypes may have different etiologies or even of genetic susceptibility factors (POP polymorphism of detoxification enzymes). Thus, POPCASE study examines the association between the presence of breast cancer and the levels and exposure profiles to a group of POPs measured in adipose tissue (AT) and blood, in particular using spectrometric methods developed by the team LABERCA (Nantes, France). These internal levels of POPs (organochlorine pesticides, dioxins, PCBs, brominated flame retardants) will be measured both quantitatively (tissue concentrations) and qualitative (relative proportions of different pollutants sought). </s>

<s>[INST] Provide title for trial id: NCT02890095 [/INST] Persistent Organic Pollutants and Breast Cancers (POPCASE) </s>

<s>[INST] Provide the recruitment status for trial id: NCT02890095 [/INST] Recruiting </s>

<s>[INST] Provide the medical condition for trial id: NCT02890095 [/INST] Breast Cancer </s>

<s>Trial Id: Prospective Screening for Breast Cancer-related Lymphedema Recruitment Status: Recruiting Trail description: The primary objectives of this study are twofold: 1) to detect and determine the level of symptoms, functional disability, and changes in quality of life that breast cancer patients experience from changes in their arms during and after treatment for breast cancer by collecting patient reported outcome measures, objective measurements, and clinical information in a prospectively maintained database and 2) to improve breast cancer-related lymphedema outcomes by early detection using objective measurements and symptoms assessments and assess these outcomes by maintaining the data in a database in order to contribute to the literature. The secondary aim of this study is to assess extracellular fluid content in the upper extremity, breast, and/or trunk of patients treated for breast cancer before, during, and after treatment in order to better understand the role of bioimpedance spectroscopy in lymphedema screening. Inclusion Criteria: Confirmed diagnosis of breast cancer Ability to obtain physical positioning for perometry (e.g. abducting shoulder to 90 degrees) and BIS measurements (e.g. standing without aid) Exclusion Criteria: Evidence of distant metastatic disease that may cause edema, Previous breast cancer History of lymphedema Pregnancy at the time of accrual and/or cardiac implants (contraindications for BIS) Medical conditions that cause fluid retention or swelling (e.g. axillary cancer recurrence, renal insufficiency, congestive heart failure). </s>

<s>[INST] Provide inclusion criteria for trial id: NCT01521741 [/INST] Confirmed diagnosis of breast cancer Ability to obtain physical positioning for perometry (e.g. abducting shoulder to 90 degrees) and BIS measurements (e.g. standing without aid) </s>

<s>[INST] Provide exclusion criteria for trial id: NCT01521741 [/INST] Evidence of distant metastatic disease that may cause edema, Previous breast cancer History of lymphedema Pregnancy at the time of accrual and/or cardiac implants (contraindications for BIS) Medical conditions that cause fluid retention or swelling (e.g. axillary cancer recurrence, renal insufficiency, congestive heart failure). </s>

<s>[INST] Provide description for trial id: NCT01521741 [/INST] The primary objectives of this study are twofold: 1) to detect and determine the level of symptoms, functional disability, and changes in quality of life that breast cancer patients experience from changes in their arms during and after treatment for breast cancer by collecting patient reported outcome measures, objective measurements, and clinical information in a prospectively maintained database and 2) to improve breast cancer-related lymphedema outcomes by early detection using objective measurements and symptoms assessments and assess these outcomes by maintaining the data in a database in order to contribute to the literature. The secondary aim of this study is to assess extracellular fluid content in the upper extremity, breast, and/or trunk of patients treated for breast cancer before, during, and after treatment in order to better understand the role of bioimpedance spectroscopy in lymphedema screening. </s>

<s>[INST] Provide title for trial id: NCT01521741 [/INST] Prospective Screening for Breast Cancer-related Lymphedema </s>

<s>[INST] Provide the recruitment status for trial id: NCT01521741 [/INST] Recruiting </s>

<s>[INST] Provide the medical condition for trial id: NCT01521741 [/INST] Lymphedema </s>

<s>Trial Id: Role of Ultrasound-Guided Lymph Node Biopsy in Axillary Staging of Breast Cancer. Recruitment Status: Unknown status Trail description: The purpose of the study is to estimate the diagnostic accuracy of preoperative ultrasound-guided axillary lymph node biopsy for staging in patients with newly diagnosed breast cancer, and also to compare between ultrasound-guided fine needle aspiration cytology and core needle biopsy in their ability to detect metastatic disease in the axillary lymph nodes of patients with breast cancer. Inclusion Criteria: Newly diagnosed patients with operable breast cancer regardless of whether lymph nodes are suspicious or not. Exclusion Criteria: Patients who had previously undergone axillary surgery. Patients with metastatic disease and not planned for axillary surgery. Patients with a preoperative diagnosis of a benign lesion or ductal carcinoma in situ. Patients with severe uncorrectable bleeding diathesis. Patients refused to sign consent. </s>

<s>[INST] Provide inclusion criteria for trial id: NCT03681418 [/INST] Newly diagnosed patients with operable breast cancer regardless of whether lymph nodes are suspicious or not. </s>

<s>[INST] Provide exclusion criteria for trial id: NCT03681418 [/INST] Patients who had previously undergone axillary surgery. Patients with metastatic disease and not planned for axillary surgery. Patients with a preoperative diagnosis of a benign lesion or ductal carcinoma in situ. Patients with severe uncorrectable bleeding diathesis. Patients refused to sign consent. </s>

<s>[INST] Provide description for trial id: NCT03681418 [/INST] The purpose of the study is to estimate the diagnostic accuracy of preoperative ultrasound-guided axillary lymph node biopsy for staging in patients with newly diagnosed breast cancer, and also to compare between ultrasound-guided fine needle aspiration cytology and core needle biopsy in their ability to detect metastatic disease in the axillary lymph nodes of patients with breast cancer. </s>

<s>[INST] Provide title for trial id: NCT03681418 [/INST] Role of Ultrasound-Guided Lymph Node Biopsy in Axillary Staging of Breast Cancer. </s>

<s>[INST] Provide the recruitment status for trial id: NCT03681418 [/INST] Unknown status </s>

<s>[INST] Provide the medical condition for trial id: NCT03681418 [/INST] Breast Cancer </s>

<s>Trial Id: Avoiding Low-value Treatments in Older Women With Early-stage Breast Cancer: Piloting a Patient Decision Aid Recruitment Status: Completed Trail description: The aim of this study is to learn whether participants find a patient guide to breast cancer treatment decisions acceptable and appropriate for use. Inclusion Criteria: None Exclusion Criteria: None </s>

<s>[INST] Provide inclusion criteria for trial id: NCT05140252 [/INST] None </s>

<s>[INST] Provide exclusion criteria for trial id: NCT05140252 [/INST] None </s>

<s>[INST] Provide description for trial id: NCT05140252 [/INST] The aim of this study is to learn whether participants find a patient guide to breast cancer treatment decisions acceptable and appropriate for use. </s>

<s>[INST] Provide title for trial id: NCT05140252 [/INST] Avoiding Low-value Treatments in Older Women With Early-stage Breast Cancer: Piloting a Patient Decision Aid </s>

<s>[INST] Provide the recruitment status for trial id: NCT05140252 [/INST] Completed </s>

<s>[INST] Provide the medical condition for trial id: NCT05140252 [/INST] Breast Cancer </s>

<s>Trial Id: Anti-Tumor Immunity Induced by Cryoablation of Invasive Breast Cancers Recruitment Status: Terminated Trail description: This protocol will study the impact of cryoablation on immune response in patients diagnosed with invasive breast cancers smaller than 1.5 cm. It will profile the immune response to cryoablation of invasive breast cancers. The intra-tumoral and systemic immune response to cryoablation will be determined and compared to pre-ablated breast cancer specimens and historical control specimens. Inclusion Criteria: Subjects with an invasive breast cancer 1.5 cm or less The breast cancer must be of ductal histology, unifocal, estrogen receptor positive and her2/neu negative. The tumor must be visible by ultrasound and the subject must not have had prior surgical resection of the primary lesion. A clip marking the breast cancer must have been placed at the time of initial diagnosis or will be placed prior to cryotherapy. The breast cancer must be amenable to cryoablation (visible by ultrasound and more than 2 mm from skin or chest wall). Subjects with metastatic disease at diagnosis who elect to have their primary tumor excised are eligible for enrollment. For subjects with breast implants, the treating physician must document that adequate distance exists between the lesion and the implant to ensure that the ablated lesion with not contact or jeopardize the implant. Subjects must be able to provide consent. Exclusion Criteria: Subjects with breast cancers of lobular histology, with lymph vascular invasion or extensive intraductal component will be excluded. Subjects with multi-centric or multi-focal breast cancers Subjects with breast cancers that have invaded skin or have significant skin tethering (assessed clinically). Subjects receiving chemotherapy within one year or undergoing neoadjuvant chemotherapy are excluded. Subjects with metastatic disease at diagnosis will be excluded unless they elect definitive surgical therapy for their primary lesion. Subjects with breast cancers not amenable to cryoablation (lesions not visible by ultrasound, against the chest wall or within 2 mm of skin) will be excluded. Subjects diagnosed with another malignancy in the preceding 5 years will be excluded. Subjects diagnosed with simultaneous bilateral breast cancer. Subjects receiving immunosuppressive therapy within 6 months including oral steroids will be excluded. </s>

<s>[INST] Provide inclusion criteria for trial id: NCT01856036 [/INST] Subjects with an invasive breast cancer 1.5 cm or less The breast cancer must be of ductal histology, unifocal, estrogen receptor positive and her2/neu negative. The tumor must be visible by ultrasound and the subject must not have had prior surgical resection of the primary lesion. A clip marking the breast cancer must have been placed at the time of initial diagnosis or will be placed prior to cryotherapy. The breast cancer must be amenable to cryoablation (visible by ultrasound and more than 2 mm from skin or chest wall). Subjects with metastatic disease at diagnosis who elect to have their primary tumor excised are eligible for enrollment. For subjects with breast implants, the treating physician must document that adequate distance exists between the lesion and the implant to ensure that the ablated lesion with not contact or jeopardize the implant. Subjects must be able to provide consent. </s>

<s>[INST] Provide exclusion criteria for trial id: NCT01856036 [/INST] Subjects with breast cancers of lobular histology, with lymph vascular invasion or extensive intraductal component will be excluded. Subjects with multi-centric or multi-focal breast cancers Subjects with breast cancers that have invaded skin or have significant skin tethering (assessed clinically). Subjects receiving chemotherapy within one year or undergoing neoadjuvant chemotherapy are excluded. Subjects with metastatic disease at diagnosis will be excluded unless they elect definitive surgical therapy for their primary lesion. Subjects with breast cancers not amenable to cryoablation (lesions not visible by ultrasound, against the chest wall or within 2 mm of skin) will be excluded. Subjects diagnosed with another malignancy in the preceding 5 years will be excluded. Subjects diagnosed with simultaneous bilateral breast cancer. Subjects receiving immunosuppressive therapy within 6 months including oral steroids will be excluded. </s>

<s>[INST] Provide description for trial id: NCT01856036 [/INST] This protocol will study the impact of cryoablation on immune response in patients diagnosed with invasive breast cancers smaller than 1.5 cm. It will profile the immune response to cryoablation of invasive breast cancers. The intra-tumoral and systemic immune response to cryoablation will be determined and compared to pre-ablated breast cancer specimens and historical control specimens. </s>

<s>[INST] Provide title for trial id: NCT01856036 [/INST] Anti-Tumor Immunity Induced by Cryoablation of Invasive Breast Cancers </s>

<s>[INST] Provide the recruitment status for trial id: NCT01856036 [/INST] Terminated </s>

<s>[INST] Provide the medical condition for trial id: NCT01856036 [/INST] Breast Cancer </s>

<s>Trial Id: Cluster Randomized Trial Comparing Interventions to Enhance Genetic Counseling Among Breast Cancer Patients Recruitment Status: Completed Trail description: RATIONALE: Multi-faceted provider education and decision support intervention will increase the rate of appropriate referral of breast cancer patients at increased risk for hereditary breast and ovarian cancer (HBOC) to genetic counseling. PURPOSE: This cluster randomized controlled trial will compare active and passive interventions to increase the rate of appropriate genetic counseling referrals of newly diagnosed breast cancer patients at increased risk for HBOC to genetic counseling in the community oncology setting. Inclusion Criteria: None Exclusion Criteria: None </s>

<s>[INST] Provide inclusion criteria for trial id: NCT01789684 [/INST] None </s>

<s>[INST] Provide exclusion criteria for trial id: NCT01789684 [/INST] None </s>

<s>[INST] Provide description for trial id: NCT01789684 [/INST] RATIONALE: Multi-faceted provider education and decision support intervention will increase the rate of appropriate referral of breast cancer patients at increased risk for hereditary breast and ovarian cancer (HBOC) to genetic counseling. PURPOSE: This cluster randomized controlled trial will compare active and passive interventions to increase the rate of appropriate genetic counseling referrals of newly diagnosed breast cancer patients at increased risk for HBOC to genetic counseling in the community oncology setting. </s>

<s>[INST] Provide title for trial id: NCT01789684 [/INST] Cluster Randomized Trial Comparing Interventions to Enhance Genetic Counseling Among Breast Cancer Patients </s>

<s>[INST] Provide the recruitment status for trial id: NCT01789684 [/INST] Completed </s>

<s>[INST] Provide the medical condition for trial id: NCT01789684 [/INST] Breast Cancer </s>

<s>Trial Id: Benefits of Breast MRI for Predicting of Histopathologic Cell Type of Small Breast Cancer Recruitment Status: Unknown status Trail description: This study examines the additional benefits of magnetic resonance imaging (MRI) with Gadovist in early breast cancer with poor prognostic features. Inclusion Criteria: Patients with invasive ductal carcinoma Patients undergoing DCE-MRI scan which are assessed according to BI-RADS lexicon Breast cancer patients with pathological diagnosed invasive ductal carcinoma with hormonal receptor (ER, PR and HER-2) response Patients who have signed on informed consent form Patients will undergo MRI imaging and the physicians will practice according to practice guidelines. Exclusion Criteria: Patients under 18 years old or during pregnancy Patients with MRI's contraindications e.g. patients with cardiac pacemaker or are allergic to MRI contrast agent Patients with unstable clinical abnormality and might get unexpected clinical treatment </s>

<s>[INST] Provide inclusion criteria for trial id: NCT01597999 [/INST] Patients with invasive ductal carcinoma Patients undergoing DCE-MRI scan which are assessed according to BI-RADS lexicon Breast cancer patients with pathological diagnosed invasive ductal carcinoma with hormonal receptor (ER, PR and HER-2) response Patients who have signed on informed consent form Patients will undergo MRI imaging and the physicians will practice according to practice guidelines. </s>

<s>[INST] Provide exclusion criteria for trial id: NCT01597999 [/INST] Patients under 18 years old or during pregnancy Patients with MRI's contraindications e.g. patients with cardiac pacemaker or are allergic to MRI contrast agent Patients with unstable clinical abnormality and might get unexpected clinical treatment </s>

<s>[INST] Provide description for trial id: NCT01597999 [/INST] This study examines the additional benefits of magnetic resonance imaging (MRI) with Gadovist in early breast cancer with poor prognostic features. </s>

<s>[INST] Provide title for trial id: NCT01597999 [/INST] Benefits of Breast MRI for Predicting of Histopathologic Cell Type of Small Breast Cancer </s>

<s>[INST] Provide the recruitment status for trial id: NCT01597999 [/INST] Unknown status </s>

<s>[INST] Provide the medical condition for trial id: NCT01597999 [/INST] Invasive Breast Cancer </s>

<s>Trial Id: The Effect of a Patient Decision Aids for Breast Cancer Screening Recruitment Status: Unknown status Trail description: Breast cancer is one of the most common cancers in Chile. National efforts focus on early detection, offering universal access to breast cancer screening through mammography to women at risk age. However, 30% of women do not undertake the exam due to a lack of knowledge and anxiety when facing the decision. The aim of this study is to develop and evaluate the effectiveness of a decision aid (DA) for women facing breast cancer screening decision in the country. Methods: following the Medical Research Council guidelines for the development and implementation of a complex intervention in public health, the investigators have: 1) culturally adapted the German DA for mammography; 2) conducted focus groups with experts to further develop the DA; 3) pilot-tested the online DA with 20 women in primary care centres. A total of 3,269 women aged 50 to 69 years old are invited to join the study. The intervention group accesses a webpage, answers a set of questionnaires at baseline, and then the DA (developed according to the IPDAS recommendations). The Control group accesses a webpage, answers a set of questionnaires at baseline, and then receives standardised information given by the healthcare system. Both groups complete the questionnaires two weeks later. The primary outcome measure is an adapted and validated version of Informed Choice. Additionally, decisional conflict, anxiety, and screening undertake rate are measured. Multiple lineal regression analysis will be conducted. Inclusion Criteria: Women from 50 to 69 years old Attend the primary care centres Fluent in Spanish Exclusion Criteria: Women with a personal history of breast cancer Have a current mammogram (as recommended by the Chilean Ministry of Health) Not having the capacity to consent. </s>

<s>[INST] Provide inclusion criteria for trial id: NCT04948983 [/INST] Women from 50 to 69 years old Attend the primary care centres Fluent in Spanish </s>

<s>[INST] Provide exclusion criteria for trial id: NCT04948983 [/INST] Women with a personal history of breast cancer Have a current mammogram (as recommended by the Chilean Ministry of Health) Not having the capacity to consent. </s>

<s>[INST] Provide description for trial id: NCT04948983 [/INST] Breast cancer is one of the most common cancers in Chile. National efforts focus on early detection, offering universal access to breast cancer screening through mammography to women at risk age. However, 30% of women do not undertake the exam due to a lack of knowledge and anxiety when facing the decision. The aim of this study is to develop and evaluate the effectiveness of a decision aid (DA) for women facing breast cancer screening decision in the country. Methods: following the Medical Research Council guidelines for the development and implementation of a complex intervention in public health, the investigators have: 1) culturally adapted the German DA for mammography; 2) conducted focus groups with experts to further develop the DA; 3) pilot-tested the online DA with 20 women in primary care centres. A total of 3,269 women aged 50 to 69 years old are invited to join the study. The intervention group accesses a webpage, answers a set of questionnaires at baseline, and then the DA (developed according to the IPDAS recommendations). The Control group accesses a webpage, answers a set of questionnaires at baseline, and then receives standardised information given by the healthcare system. Both groups complete the questionnaires two weeks later. The primary outcome measure is an adapted and validated version of Informed Choice. Additionally, decisional conflict, anxiety, and screening undertake rate are measured. Multiple lineal regression analysis will be conducted. </s>

<s>[INST] Provide title for trial id: NCT04948983 [/INST] The Effect of a Patient Decision Aids for Breast Cancer Screening </s>

<s>[INST] Provide the recruitment status for trial id: NCT04948983 [/INST] Unknown status </s>

<s>[INST] Provide the medical condition for trial id: NCT04948983 [/INST] Breast Cancer, Mammary Cancer, Breast Tumor, Mammary Tumor </s>

<s>Trial Id: Case-Control-Study on the Breast Cancer Risk of Mirena® Compared With Copper IUDs Recruitment Status: Completed Trail description: The objective of this study is to determine the breast cancer risk of Mirena® users compared to copper intrauterine device (IUD) users in a community-based case-control study. Inclusion Criteria: cases: women with a breast cancer who are younger than 50 years of age at cancer diagnosis controls: women without a breast cancer diagnosis who are younger than 50 years at the time of the interview Exclusion Criteria: women who are not willing to participate </s>

<s>[INST] Provide inclusion criteria for trial id: NCT00461253 [/INST] cases: women with a breast cancer who are younger than 50 years of age at cancer diagnosis controls: women without a breast cancer diagnosis who are younger than 50 years at the time of the interview </s>

<s>[INST] Provide exclusion criteria for trial id: NCT00461253 [/INST] women who are not willing to participate </s>

<s>[INST] Provide description for trial id: NCT00461253 [/INST] The objective of this study is to determine the breast cancer risk of Mirena® users compared to copper intrauterine device (IUD) users in a community-based case-control study. </s>

<s>[INST] Provide title for trial id: NCT00461253 [/INST] Case-Control-Study on the Breast Cancer Risk of Mirena® Compared With Copper IUDs </s>

<s>[INST] Provide the recruitment status for trial id: NCT00461253 [/INST] Completed </s>

<s>[INST] Provide the medical condition for trial id: NCT00461253 [/INST] Breast Cancer </s>

<s>Trial Id: Clinical Pilot Study for Personalized Risk-based Breast Cancer Screening Recruitment Status: Recruiting Trail description: The study aims to evaluate the impact of implementing population-based genetics testing strategy for breast cancer precision prevention using the polygenic risk score and monogenic pathogenic variant (MPV) testing in the Norwegian healthcare setting. Inclusion Criteria: Women referred for clinical mammography in the Vestre Viken Breast Centre Breast density BI-RADS a or d 40-50 y.o. Exclusion Criteria: Prior history of breast cancer or premalignant breast disease Prior genetic counselling/testing </s>

<s>[INST] Provide inclusion criteria for trial id: NCT05731453 [/INST] Women referred for clinical mammography in the Vestre Viken Breast Centre Breast density BI-RADS a or d 40-50 y.o. </s>

<s>[INST] Provide exclusion criteria for trial id: NCT05731453 [/INST] Prior history of breast cancer or premalignant breast disease Prior genetic counselling/testing </s>

<s>[INST] Provide description for trial id: NCT05731453 [/INST] The study aims to evaluate the impact of implementing population-based genetics testing strategy for breast cancer precision prevention using the polygenic risk score and monogenic pathogenic variant (MPV) testing in the Norwegian healthcare setting. </s>

<s>[INST] Provide title for trial id: NCT05731453 [/INST] Clinical Pilot Study for Personalized Risk-based Breast Cancer Screening </s>

<s>[INST] Provide the recruitment status for trial id: NCT05731453 [/INST] Recruiting </s>

<s>[INST] Provide the medical condition for trial id: NCT05731453 [/INST] Breast Cancer </s>

<s>Trial Id: Monitoring and Predicting Breast Cancer Neoadjuvant Chemotherapy Response Using Diffuse Optical Spectroscopic Imaging Recruitment Status: Withdrawn Trail description: The investigators have developed imaging protocols to monitor and predict breast cancer response to neoadjuvant chemotherapy, both prior to and as early as possible during the course of treatment. The efficacy and practicality of conventional imaging approaches in the neoadjuvant chemotherapy setting varies and identifies the need for alternate functional imaging strategies. Diffuse optical spectroscopic imaging is an experimental imaging method that allows patients to be followed from baseline through treatment and surgery with a cost-effective, bedside, handheld scanning probe. The researcher evaluates a harmonized diffuse optical spectroscopic imaging technology platform that has been standardized for neoadjuvant chemotherapy monitoring. Diffuse optical spectroscopic imaging is an academic research platform that is non-invasive. Studies will be performed in five clinical sites on approximately 60 neoadjuvant chemotherapy patients. Inclusion Criteria: Female, 18 years of age or older, non pregnant or nursing. Diagnosis of breast cancer and will be receiving chemo therapy treatments Exclusion Criteria: 18 years of age or younger, pregnant or nursing. Previous treatment including chemo therapy, radiation, surgery, and hormone therapy. Previous diagnosis with other form of cancer. </s>

<s>[INST] Provide inclusion criteria for trial id: NCT01257932 [/INST] Female, 18 years of age or older, non pregnant or nursing. Diagnosis of breast cancer and will be receiving chemo therapy treatments </s>

<s>[INST] Provide exclusion criteria for trial id: NCT01257932 [/INST] 18 years of age or younger, pregnant or nursing. Previous treatment including chemo therapy, radiation, surgery, and hormone therapy. Previous diagnosis with other form of cancer. </s>

<s>[INST] Provide description for trial id: NCT01257932 [/INST] The investigators have developed imaging protocols to monitor and predict breast cancer response to neoadjuvant chemotherapy, both prior to and as early as possible during the course of treatment. The efficacy and practicality of conventional imaging approaches in the neoadjuvant chemotherapy setting varies and identifies the need for alternate functional imaging strategies. Diffuse optical spectroscopic imaging is an experimental imaging method that allows patients to be followed from baseline through treatment and surgery with a cost-effective, bedside, handheld scanning probe. The researcher evaluates a harmonized diffuse optical spectroscopic imaging technology platform that has been standardized for neoadjuvant chemotherapy monitoring. Diffuse optical spectroscopic imaging is an academic research platform that is non-invasive. Studies will be performed in five clinical sites on approximately 60 neoadjuvant chemotherapy patients. </s>

<s>[INST] Provide title for trial id: NCT01257932 [/INST] Monitoring and Predicting Breast Cancer Neoadjuvant Chemotherapy Response Using Diffuse Optical Spectroscopic Imaging </s>

<s>[INST] Provide the recruitment status for trial id: NCT01257932 [/INST] Withdrawn </s>

<s>[INST] Provide the medical condition for trial id: NCT01257932 [/INST] Breast Cancer </s>

<s>Trial Id: Investigating the Metabolic Pathways in Hormone Receptor Positive/HER2 Negative Breast Cancer Recruitment Status: Not yet recruiting Trail description: To analyze the metabolic activity of Hormone Receptor Positive (HR+)/Her 2 Negative (Her2-) Breast cancer. Inclusion Criteria: Have hormone receptor (HR) positive [estrogen receptor( ER)+/progesterone receptor (PR)+, ER+/PR- or ER-/PR+)/Her2 negative breast cancer previously diagnosed by biopsy. Have early stage, clinical or anatomic stage I, II or III breast cancer (cT1cN0, cT1cN1, cT2N0, cT2N1, cT3N0) Candidates for intended curative primary resection who have not had neoadjuvant therapy (endocrine/hormonal therapy, chemotherapy with or without immunotherapy). Willing to undergo mandatory intraoperative small excisional and core biopsies (4-6 passes) of tumor and normal tissue for research purposes at the time of proposed surgical resection. Exclusion Criteria: Is currently enrolled, or will enroll in, a different clinical study in which investigational therapeutic procedures are performed or investigational therapies are administered while participating in this study. Has triple negative (ER-/PR-/Her2-) or HER2+ breast cancer. Concomitant active malignancy Is of child-bearing potential who has not had a recent negative pregnancy test done outside of this clinical trial (i.e., as part of standard preparation for diagnosis and treatment for her cancer) </s>

<s>[INST] Provide inclusion criteria for trial id: NCT05736367 [/INST] Have hormone receptor (HR) positive [estrogen receptor( ER)+/progesterone receptor (PR)+, ER+/PR- or ER-/PR+)/Her2 negative breast cancer previously diagnosed by biopsy. Have early stage, clinical or anatomic stage I, II or III breast cancer (cT1cN0, cT1cN1, cT2N0, cT2N1, cT3N0) Candidates for intended curative primary resection who have not had neoadjuvant therapy (endocrine/hormonal therapy, chemotherapy with or without immunotherapy). Willing to undergo mandatory intraoperative small excisional and core biopsies (4-6 passes) of tumor and normal tissue for research purposes at the time of proposed surgical resection. </s>

<s>[INST] Provide exclusion criteria for trial id: NCT05736367 [/INST] Is currently enrolled, or will enroll in, a different clinical study in which investigational therapeutic procedures are performed or investigational therapies are administered while participating in this study. Has triple negative (ER-/PR-/Her2-) or HER2+ breast cancer. Concomitant active malignancy Is of child-bearing potential who has not had a recent negative pregnancy test done outside of this clinical trial (i.e., as part of standard preparation for diagnosis and treatment for her cancer) </s>

<s>[INST] Provide description for trial id: NCT05736367 [/INST] To analyze the metabolic activity of Hormone Receptor Positive (HR+)/Her 2 Negative (Her2-) Breast cancer. </s>

<s>[INST] Provide title for trial id: NCT05736367 [/INST] Investigating the Metabolic Pathways in Hormone Receptor Positive/HER2 Negative Breast Cancer </s>

<s>[INST] Provide the recruitment status for trial id: NCT05736367 [/INST] Not yet recruiting </s>

<s>[INST] Provide the medical condition for trial id: NCT05736367 [/INST] Breast Cancer </s>

<s>Trial Id: Evaluation of Degree of Conversion of HER2 Receptor Between Primary Breast Cancer and Metastasis Recruitment Status: Completed Trail description: This is a Prospective Clinical Trial without drugs, to determine the HER2 status in the metastasis of patients with primary breast cancer HER2. 32 Sites have been taking part in this Clinical Trial. Inclusion Criteria: Patients who have given their written informed consent to participate in the study. Women over 18 years. Breast cancer locally recurrent or metastatic at first relapse or after successive progressions. Patient has to have available a sample of the primary tumor in paraffin. Patients who are planning for the next 6 weeks, the biopsy (fine needle aspiration / drainage of fluid cavities, open biopsy, core biopsy) of locally recurrent or metastatic lesion [local relapse in the chest wall, nodal , cutaneous or subcutaneous metastases, peripheral lymph nodes and other soft tissues accessible, bone metastases, visceral metastases (lung, liver, brain, etc..) or pleural effusion / ascites / pericardial / cerebrospinal] according to clinical practice center. Exclusion Criteria: Patients with cognitive impairment that might impede a proper understanding of the written informed consent, according to medical criteria. Ipsilateral breast local relapses or contralateral breast away. Patients diagnosed with a second neoplasm, with the exception of cervical carcinoma in situ and non-melanoma skin carcinoma treated properly. </s>

<s>[INST] Provide inclusion criteria for trial id: NCT01377363 [/INST] Patients who have given their written informed consent to participate in the study. Women over 18 years. Breast cancer locally recurrent or metastatic at first relapse or after successive progressions. Patient has to have available a sample of the primary tumor in paraffin. Patients who are planning for the next 6 weeks, the biopsy (fine needle aspiration / drainage of fluid cavities, open biopsy, core biopsy) of locally recurrent or metastatic lesion [local relapse in the chest wall, nodal , cutaneous or subcutaneous metastases, peripheral lymph nodes and other soft tissues accessible, bone metastases, visceral metastases (lung, liver, brain, etc..) or pleural effusion / ascites / pericardial / cerebrospinal] according to clinical practice center. </s>

<s>[INST] Provide exclusion criteria for trial id: NCT01377363 [/INST] Patients with cognitive impairment that might impede a proper understanding of the written informed consent, according to medical criteria. Ipsilateral breast local relapses or contralateral breast away. Patients diagnosed with a second neoplasm, with the exception of cervical carcinoma in situ and non-melanoma skin carcinoma treated properly. </s>

<s>[INST] Provide description for trial id: NCT01377363 [/INST] This is a Prospective Clinical Trial without drugs, to determine the HER2 status in the metastasis of patients with primary breast cancer HER2. 32 Sites have been taking part in this Clinical Trial. </s>

<s>[INST] Provide title for trial id: NCT01377363 [/INST] Evaluation of Degree of Conversion of HER2 Receptor Between Primary Breast Cancer and Metastasis </s>

<s>[INST] Provide the recruitment status for trial id: NCT01377363 [/INST] Completed </s>

<s>[INST] Provide the medical condition for trial id: NCT01377363 [/INST] Breast Cancer </s>

<s>Trial Id: PROSPR/PCIPS Project 3: Communication of Personalized Breast Cancer Risk Recruitment Status: Completed Trail description: In order to better communicate personal risk of breast cancer to women who have not yet initiated breast cancer screening (mammography), The Annenberg School of Communication at the University of Pennsylvania has created a personal breast cancer screening decision aid tool. This tool will be pilot tested, and then implemented and tested in nine primary care and OB/GYN practices within the University of Pennsylvania Health System. Inclusion Criteria: Women ages 39-48 Patient of one of the nine primary care or OB/GYN practices that are participating in the study Must have had an appointment at one of these locations in the past 24 months Must have an appointment during the study period Woman has not yet initiated breast cancer screening (no prior mammogram) No history of breast cancer Exclusion Criteria: Prior diagnosis of breast cancer Major comorbidity that substantially affects their 10 year mortality Non-English speaker </s>

<s>[INST] Provide inclusion criteria for trial id: NCT01879189 [/INST] Women ages 39-48 Patient of one of the nine primary care or OB/GYN practices that are participating in the study Must have had an appointment at one of these locations in the past 24 months Must have an appointment during the study period Woman has not yet initiated breast cancer screening (no prior mammogram) No history of breast cancer </s>

<s>[INST] Provide exclusion criteria for trial id: NCT01879189 [/INST] Prior diagnosis of breast cancer Major comorbidity that substantially affects their 10 year mortality Non-English speaker </s>

<s>[INST] Provide description for trial id: NCT01879189 [/INST] In order to better communicate personal risk of breast cancer to women who have not yet initiated breast cancer screening (mammography), The Annenberg School of Communication at the University of Pennsylvania has created a personal breast cancer screening decision aid tool. This tool will be pilot tested, and then implemented and tested in nine primary care and OB/GYN practices within the University of Pennsylvania Health System. </s>

<s>[INST] Provide title for trial id: NCT01879189 [/INST] PROSPR/PCIPS Project 3: Communication of Personalized Breast Cancer Risk </s>

<s>[INST] Provide the recruitment status for trial id: NCT01879189 [/INST] Completed </s>